810
Participants
Start Date
April 16, 2019
Primary Completion Date
August 11, 2021
Study Completion Date
December 31, 2025
Durvalumab
IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
Placebo
IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
Research Site, Taoyuan District
Research Site, Chiayi City
Research Site, Tainan City
Research Site, Ciudad de Buenos Aires
Research Site, Sofia
Research Site, Sofia
Research Site, Sofia
Research Site, Rosario
Research Site, San Salvador de Jujuy
Research Site, Nice
Research Site, Burgas
Research Site, Varna
Research Site, Taipei
Research Site, Bangkok
Research Site, Bangkok
Research Site, Taipei
Research Site, Seongnam-si
Research Site, Philadelphia
Research Site, Washington D.C.
Research Site, Milan
Research Site, Dijon
Research Site, Chapel Hill
Research Site, Si Sa Ket
Research Site, Mersin
Research Site, Pessac
Research Site, St. Petersburg
Research Site, Fort Myers
Research Site, Istanbul
Research Site, Montpellier
Research Site, Izmir
Research Site, Verona
Research Site, Nashville
Research Site, Chattanooga
Research Site, Khon Kaen
Research Site, Louisville
Research Site, Taichung
Research Site, Faenza
Research Site, Florence
Research Site, Muang
Research Site, St Louis
Research Site, Westwood
Research Site, Paris
Research Site, Napoli
Research Site, Kaohsiung City
Research Site, Kaohsiung City
Research Site, Poitiers
Research Site, Los Angeles
Research Site, Hat Yai
Research Site, Clichy
Research Site, Orange
Research Site, Portland
Research Site, Seattle
Research Site, Shenyang
Research Site, Beijing
Research Site, Beijing
Research Site, New Delhi
Research Site, Moscow
Research Site, Moscow
Research Site, Gūrgaon
Research Site, Moscow
Research Site, Hong Kong
Research Site, Harbin
Research Site, Kostroma
Research Site, Saint Petersburg
Research Site, Saint Petersburg
Research Site, Shanghai
Research Site, Nanjing
Research Site, Suzhou
Research Site, Hefei
Research Site, Hefei
Research Site, Bengbu
Research Site, Jinan
Research Site, Hangzhou
Research Site, Hangzhou
Research Site, Nanchang
Research Site, Mumbai
Research Site, Chongqing
Research Site, Zhengzhou
Research Site, Guangzhou
Research Site, Zhuhai
Research Site, Foshan
Research Site, Omsk
Research Site, Barnaul
Research Site, Kolkata
Research Site, Xi'an
Research Site, Temuco
Research Site, Santiago
Research Site, Burlington
Research Site, Buenos Aires
Research Site, Buenos Aires
Research Site, CABA
Research Site, CABA
Research Site, Baoding
Research Site, Shandong
Research Site, Hong Kong
Research Site, Kowloon
Research Site, Hong Kong
Research Site, Roma
Research Site, Chūōku
Research Site, Kashiwa
Research Site, Kitaadachi-gun
Research Site, Mitaka-shi
Research Site, Osaka
Research Site, Suita-shi
Research Site, Wakayama
Research Site, Yokohama
Research Site, Gdansk
Research Site, Lodz
Research Site, Olsztyn
Research Site, Poznan
Research Site, Warsaw
Research Site, Wroclaw
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Ankara
Research Site, Bristol
Research Site, Cambridge
Research Site, London
Research Site, London
Research Site, Manchester
Research Site, Oxford
Research Site, Romford
Research Site, Sheffield
Lead Sponsor
AstraZeneca
INDUSTRY